In summary, treatment with GH and an aromatase inhibitor may provide unique benefits in the setting of advanced CKD and should be considered in children who present with significant short stature close to puberty when time for other therapeutic options is limited. The gene discussed is CYP19A1; the disease is chronic kidney disease.